Treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimer's disease and inflammatory bowel disease by using at least one bacterial strain from prevotella

Abstract

A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, Alzheimer's disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, wherein the strain is selected from the group consisting of Prevotella copri, Prevotella stercorea, Prevotella histicola, Prevotella ruminicola, Prevotella Bryantii 25A and Prevotella distasonis. The product may be a food product.

1 . A method of treating obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, or Alzheimer's disease comprising administering at least one bacteria elected from the group consisting of  Prevotella copri, Prevotella stercorea, Prevotella histicola, Prevotella ruminicola, Prevotella Bryantii  25A and  Prevotella distasonis  to a subject in need thereof. 
     
     
         2 . The method according to  claim 1 , wherein the at least one bacteria is  Prevotella copri.    
     
     
         3 . The method according to  claim 1 , wherein the at least one bacteria is  Prevotella Ruminicola.    
     
     
         4 . The method according to  claim 1 , wherein at least one type of dietary fiber is administered together with the administration of the at least one bacteria. 
     
     
         5 . The method according to  claim 3 , wherein at least one resistant starch is administered together with the administration of the at least one bacteria. 
     
     
         6 . The method according to  claim 1 , wherein said at least one bacteria is genetically modified. 
     
     
         7 . The method according to  claim 1 , wherein said dietary fiber comprises fiber selected from the group consisting of barley fiber, wheat fiber, lye fiber, oat fiber, and beta-glucan fiber. 
     
     
         8 . The method according to  claim 7 , wherein said dietary fiber is from barley. 
     
     
         9 . The method according to  claim 6 , wherein said resistant starch is a starch selected from the group consisting of retrograded starch, botanically encapsulated starch, native ungelatinized starch, cyclodextrins and chemically modified starch. 
     
     
         10 . The method according to  claim 1 , further comprising administering an additional bacteria to the subject, wherein said additional bacteria is a succinate producing bacteria. 
     
     
         11 . The method according to  claim 1 , further comprising administering succinate to the subject. 
     
     
         12 . The method according to  claim 1 , wherein the at least one bacteria is encapsulated or lyophilized. 
     
     
         13 . The method according to  claim 5 , wherein the said resistant starch is a starch selected from the group consisting of barley, wheat, rye, and oat. 
     
     
         14 . The method according to  claim 1 , wherein the at least one bacteria is administered in the form of a product selected from the group consisting of a food product, a food ingredient, a food supplement or medicament, wherein the food product, food ingredient and food supplement are suitable for ingestion and the medicament is suitable for use as a suppository or enema or enclosed in a capsule. 
     
     
         15 . The method according to  claim 14 , wherein the at least one bacteria is administered in the form of a food product. 
     
     
         16 . The method according to  claim 14 , wherein the food product is a probiotic food product. 
     
     
         17 . The method according to  claim 14 , wherein the at least one bacteria is present in a capsule. 
     
     
         18 . The method according to  claim 14 , wherein the at least one bacteria is formulated into one of a tablet, depot prolonged-release capsule, prolonged release granules, and a powder.